文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

西班牙HIV-1感染者整合酶链转移抑制剂原发耐药的低流行率:超敏基因型检测的前瞻性队列研究

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

本研究在西班牙开展96周前瞻性多中心队列,纳入214例未治疗HIV-1感染者,采用Sanger测序或MiSeq超敏检测(≥20%阈值)分析整合酶、逆转录酶和蛋白酶耐药。总体传播耐药率为13.1%,整合酶抑制剂相关耐药仅1.7%,低频率变异占9.6%,携带主要耐药变异者96周内无病毒学失败。

要点

  • 西班牙未治疗HIV-1感染者中传播性整合酶抑制剂耐药率低(1.7%)
  • 超敏检测发现9.6%存在低频率整合酶耐药变异
  • 携带传播耐药变异者启动基于整合酶抑制剂方案后96周无病毒学失败

核心结论

  • 西班牙HIV-1传播性整合酶抑制剂耐药仍罕见,且未导致基于整合酶抑制剂的一线方案病毒学失败。

研究设计与样本

  • 治疗前血浆样本用Sanger群体测序或MiSeq超敏检测(≥20%为突变阈值,1%-19%为低频率变异)分析整合酶、逆转录酶和蛋白酶基因。

主要发现

  • 整合酶、逆转录酶和蛋白酶基因成功扩增率分别为80.8%(173/214)、98.1%(210/214)和100.0%(214/214)。
  • 总体传播耐药率为13.1%,整合酶抑制剂、NRTI、NNRTI和蛋白酶抑制剂相关突变率分别为1.7%、3.8%、7.1%和0.9%。
  • 仅3例(1.7%)存在整合酶抑制剂传播耐药(R263K、E138K和G163R),9.6%受试者检出低频率整合酶耐药变异。
  • 携带主要传播耐药变异者在96周随访期间无病毒学失败。

临床怎么用

  • 在西班牙等低流行区,基于整合酶抑制剂的一线方案仍有效,常规治疗前耐药检测可继续监测传播耐药。
  • 超敏检测可发现低频率耐药变异,但其临床意义需进一步研究。

局限性

  • 整合酶基因仅80.8%样本成功扩增,可能影响耐药率估计的准确性。
  • 低频率变异(1%-19%)的临床影响未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy of first-line antiretroviral regimens currently recommended worldwide. Continued surveillance of transmitted drug resistance (TDR) is thus warranted. OBJECTIVES: We evaluated the rates and effects on virological outcomes of TDR in a 96 week prospective multicentre cohort study of ART-naive HIV-1-infected subjects initiating INSTI-based ART in Spain between April 2015 and December 2016. METHODS: Pre-ART plasma samples were genotyped for integrase, protease and reverse transcriptase resistance using Sanger population sequencing or MiSeq™ using a ≥ 20% mutant sensitivity cut-off. Those present at 1%-19% of the virus population were considered to be low-frequency variants. RESULTS: From a total of 214 available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genes, respectively. Using a Sanger-like cut-off, the overall prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations was 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects. There were no virological failures during 96 weeks of follow-up in subjects harbouring TDR as majority variants. CONCLUSIONS: Transmitted INSTI resistance remains rare in Spain and, to date, is not associated with virological failure to first-line INSTI-based regimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Casadellà M, Santos JR, Noguera-Julian M, et al. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. J Antimicrob Chemother. 2020. PMID: 32929472. doi:10.1093/jac/dkaa349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。